DarioHealth (DRIO) Misses Q3 EPS by 3c, Revenues Beat

DarioHealth (NASDAQ: DRIO) reported Q3 EPS of ($0.71), $0.03 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $2.04 million versus the consensus estimate of $1.95 million.

"During the third quarter we achieved 14.2% sequential growth in our revenues, but more importantly, we made significant strides in penetrating the multiple verticals within the Business-to-Business-to-Consumer (B2B2C) channel with our digital therapeutics solutions," stated Erez Raphael, Chief Executive Officer of Dario. "Most notably, our recently announced partnership agreements with Vitality Group and HMC Healthworks provide access of our solutions to end users through their employers or benefits providers. We believe that our industry consumer engagement metrics and open architecture that allows for seamless integration with legacy systems are key differentiating factors relative to our competition that have resonated with customers and prospects alike.

"The execution of our multi-year, strategic plan has led to advanced late-stage contracting discussions with health plans, self-insured employers and providers. We are encouraged by the fact that we are pursuing multiple large opportunities, and we anticipate many of these agreements will close and launch in the near term. Furthermore, as our sales pipeline has grown during the third quarter, we believe that our ongoing investments in our U.S. commercial infrastructure have positioned Dario for a transformational year in 2021."

"We ended the third quarter with $37 million in cash on the balance sheet after completing a successful $28.6 million financing in July," Zvi Ben-David, Dario's Chief Financial Officer added. "This is the largest cash position in the Company's history. Our liquidity is sufficient to invest in research and development, expand our portfolio of chronic diseases and build the necessary sales and marketing infrastructure to drive further penetration of the B2B2C channel. We believe that we are funded to achieve our goals in the coming quarters."

For earnings history and earnings-related data on DarioHealth (DRIO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• StablecoinX reports Q2 2026 results with $34.2M net loss